Trial · NCT03487549
Cantharidin and Occlusion in Verruca Epithelium
NCT03487549, Phase 2, Completed, Verrica Pharmaceuticals Inc.; results first posted 2021-09-01
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Cantharidin and Occlusion in Verruca Epithelium. Trials, record NCT03487549. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03487549
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cantharidin and Occlusion in Verruca Epithelium
- NCT number
- NCT03487549
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 56 participants, actual
- Lead sponsor
- Verrica Pharmaceuticals Inc.
- Conditions
Common Wart, Warts Hand, Warts, Papillomavirus Infections, DNA Virus Infections, Skin Diseases, Viral, Skin Diseases, Infectious, Skin Diseases, Virus Diseases, Tumor Virus Infections, Verruca Vulgaris, Verruca
- Interventions
- VP-102 Cantharidin topical film forming solution, VP-102 Cantharidin, topical film forming solution
- First posted
- 2018-04-04
- Last updated
- 2024-11-27
- Results first posted
- 2021-09-01
Source ClinicalTrials.gov
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOS Visit (Day 84) | Treatment Visit Day 1 (Baseline) compared to Day 84 (EOS) Visit. | Cohort 1: Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at the EOS Visit (Day 84). |
| Primary | Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOT Visit (Day 84) | Compare Treatment Visit 1 (Baseline) to EOT Visit (Day 84) | Cohort 2: Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at the EOT Visit (Day 84). |
| Secondary | Cohort 1: Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOS Visit (Day 84) | Change in the number of warts compared at Baseline (Visit 1) to the End of Study Visit (Day 84). | Cohort 1: Change from baseline in the number of treatable warts (baseline and new) at the EOS Visit (Day 84). |
| Secondary | Cohort 1: Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOT Visit (Day 84). | Baseline (Visit 1) to End of Treatment Visit (Day 84). | Cohort 1: Assessing the percent change from Baseline in the number of treatable warts (Baseline and new) at the EOT visit (Day 84). |
| Secondary | Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study | Baseline, Day 14, 28, 42 and 84 (EOS) | Cohort 1: Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at Visit 2, Visit 3, Visit 4 and over the duration of the study. |
| Secondary | Cohort 2: Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOT Visit Day 84) | Baseline, Day 84 (EOS) | Cohort 2: Change from baseline in the number of treatable warts (baseline and new) at the EOT Visit Day 84). |
| Secondary | Cohort 2: Change From Baseline in the Percent of Treatable Warts (Baseline and New) at the EOT Visit (Day 84) | Baseline (Visit 1) to End of Treatment Visit (Day 84). | Cohort 2: Change from baseline in the percent of treatable warts (baseline and new) at the EOT Visit (Day 84). |
| Secondary | Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts, (Baseline and New), at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study | Baseline, Day 21, 42, 63, and 84 (EOS), 105, 126, and 147 | Cohort 2: Proportion of subjects exhibiting complete clearance of all treatable warts, (baseline and new), at Visit 2, Visit 3, Visit 4 and over the duration of the study. |
| Other | Cohort 1:Percent Reduction of All Treatable Warts (Baseline and New) From Baseline at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study. | Baseline, Day 14, 28, 42, and 84 (EOS) | Cohort 1: Percent change from baseline in the number of treatable warts (Baseline and new) from Baseline at Visit 2, Visit 3, Visit 4 and over the duration of the study. |
| Other | Cohort 1: Change From Baseline in the Number of Treatable Warts (Baseline and New) at Visit 2, Visit 3, Visit 4 and the EOS Visit | Baseline, Day 14, 28, 42, and 84 (EOS) | Cohort 1: Change from baseline in the number of treatable warts (baseline and new) at Visit 2, Visit 3, Visit 4 and the EOS Visit. |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 registered outcomesOutcomes21
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOS Visit (Day 84) | Treatment Visit Day 1 (Baseline) compared to Day 84 (EOS) Visit. | ITT Population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOT Visit (Day 84) | Compare Treatment Visit 1 (Baseline) to EOT Visit (Day 84) | ITT Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Cohort 1: Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOS Visit (Day 84) | Change in the number of warts compared at Baseline (Visit 1) to the End of Study Visit (Day 84). | ITT Population | Number of warts | MEAN |
| SECONDARY | Cohort 1: Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOT Visit (Day 84). | Baseline (Visit 1) to End of Treatment Visit (Day 84). | ITT Population | Percent change | MEAN |
| SECONDARY | Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study | Baseline, Day 14, 28, 42 and 84 (EOS) | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Cohort 2: Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOT Visit Day 84) | Baseline, Day 84 (EOS) | ITT Population | change in wart count | MEAN |
| SECONDARY | Cohort 2: Change From Baseline in the Percent of Treatable Warts (Baseline and New) at the EOT Visit (Day 84) | Baseline (Visit 1) to End of Treatment Visit (Day 84). | ITT Population | percentage of change in wart count | MEAN |
| SECONDARY | Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts, (Baseline and New), at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study | Baseline, Day 21, 42, 63, and 84 (EOS), 105, 126, and 147 | ITT Population | Participants | COUNT_OF_PARTICIPANTS |
| OTHER_PRE_SPECIFIED | Cohort 1:Percent Reduction of All Treatable Warts (Baseline and New) From Baseline at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study. | Baseline, Day 14, 28, 42, and 84 (EOS) | ITT Population | Percent change in number of warts | MEAN |
| OTHER_PRE_SPECIFIED | Cohort 1: Change From Baseline in the Number of Treatable Warts (Baseline and New) at Visit 2, Visit 3, Visit 4 and the EOS Visit | Baseline, Day 14, 28, 42, and 84 (EOS) | ITT Population | change in wart count | MEAN |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 outcomesResults by group57
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOS Visit (Day 84) | Cohort 1 | 4 | Participants | ||
| Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOT Visit (Day 84) | VP-102 - Cohort 2 | 18 | Participants | ||
| Cohort 1: Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOS Visit (Day 84) | Cohort 1 | Baseline | 2.19 | Standard Deviation 1.569 | Number of warts |
| Cohort 1: Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOS Visit (Day 84) | Cohort 1 | End of Treatment Visit | -0.95 | Standard Deviation 1.658 | Number of warts |
| Cohort 1: Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOT Visit (Day 84). | Cohort 1 | -31.19 | Standard Deviation 42.776 | Percent change | |
| Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study | Cohort 1 | Complete Clearance Reported at any Visit? | 5 | Participants | |
| Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study | Cohort 1 | Complete Clearance Reported at Day 14 | 0 | Participants | |
| Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study | Cohort 1 | Complete Clearance Reported at Day 28 | 2 | Participants | |
| Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study | Cohort 1 | Complete Clearance Reported at Day 42 | 5 | Participants | |
| Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study | Cohort 1 | Complete Clearance Reported at Day 84 (EOS) | 4 | Participants |
1 to 10 of 57Source ClinicalTrials.gov
See all 57 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cohort 1 | 21 | |
| Overall Study | STARTED | Cohort 2 | 35 | |
| Overall Study | COMPLETED | Cohort 1 | 17 | |
| Overall Study | COMPLETED | Cohort 2 | 33 | |
| Overall Study | NOT COMPLETED | Cohort 1 | 4 | |
| Overall Study | NOT COMPLETED | Cohort 2 | 2 |
Source ClinicalTrials.gov
Adverse events22
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Application site vesicles | General disorders | Cohort 1 | 20 | 21 | |
| other | Application site vesicles | General disorders | Cohort 2 | 27 | 34 | |
| other | Application site pain | General disorders | Cohort 1 | 20 | 21 | |
| other | Application site pain | General disorders | Cohort 2 | 26 | 34 | |
| other | Application site erythema | General disorders | Cohort 1 | 13 | 21 | |
| other | Application site erythema | General disorders | Cohort 2 | 19 | 34 | |
| other | Application site pruritus | General disorders | Cohort 1 | 9 | 21 | |
| other | Application site pruritus | General disorders | Cohort 2 | 16 | 34 | |
| other | Application site scab | General disorders | Cohort 1 | 8 | 21 | |
| other | Application site scab | General disorders | Cohort 2 | 20 | 34 |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cohort 1 | 0 | 21 |
| Total, all-cause mortality | Cohort 2 | 0 | 34 |
| Total, other adverse events | Cohort 1 | 20 | 21 |
| Total, other adverse events | Cohort 2 | 32 | 34 |
| Total, serious adverse events | Cohort 1 | 0 | 21 |
| Total, serious adverse events | Cohort 2 | 0 | 35 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 34286459 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Cohort 1 vs Cohort 2: deaths from any cause | Trial comparisons |
| Cohort 1 vs Cohort 2: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03487549
GET https://conductscience.org/api/trials/v1/NCT03487549/registered?page=2